AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

2019 Analytical Report for Healthcare Licensing with Focus on Biomarkers - ResearchAndMarkets.com

September 9, 2019

DUBLIN--(BUSINESS WIRE)--Sep 9, 2019--

The “Analytical Report for Healthcare Licensing with focus on Biomarkers” report has been added to ResearchAndMarkets.com’s offering.

Biomarker research has become an important component of the drug discovery and development process. Moreover, with the growing trend in personalized medicine and companion diagnostics, the use of biomarkers is becoming obligatory in the management of certain diseases. An in-depth update on its licensing trends is presented in this report. 50+ licensing news with a focus on Biomarkers, during January 1, 2018, to July 31, 2019, are reported and analyzed to provide a snapshot view of the current business trends.

Analytical data coverage:

User benefits:

Key Topics Covered:

Introduction

Research Design

Chapter 1: Analysis of healthcare inventions with focus on Biomarkers licensed during the past 19 months

1.1 Number of licensing deals with a focus on Biomarkers

1.2 Countries with most licensing deals with a focus on Biomarkers

1.3 Healthcare sub-sectors with most licensing deals with a focus on Biomarkers

1.4 Market capitalization groups with most licensing deals with a focus on Biomarkers

1.5 Medicine groups with most licensing deals with a focus on Biomarkers

1.6 Leading companies with most licensing deals with a focus on Biomarkers

1.7 Licensing payment arrangements most followed in licensing deals with a focus on Biomarkers

Chapter 2: Key licensing deals with a focus on Biomarkers during the past 19 months - By type of licensing deal

Chapter 3: Global healthcare inventions with focus on Biomarkers licensed during the past 19 months - By region and company name

Chapter 4: Summary and conclusions

Appendices

Appendix 1 List of companies/institutes covered

a) By region, country and company name

b) By sub-industry, country and company name

c) By market capitalization group, country and company name

d) By medicine group, country and company name

e) By terms of payment, country and company name

Appendix 2 List of non-listed companies covered - By country and company name

Appendix 3 List of not-for-profit institutes covered - By country and institute name

For more information about this report visit https://www.researchandmarkets.com/r/ewiptr

View source version on businesswire.com:https://www.businesswire.com/news/home/20190909005798/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 09/09/2019 12:43 PM/DISC: 09/09/2019 12:43 PM

http://www.businesswire.com/news/home/20190909005798/en

All contents © copyright 2019 The Associated Press. All rights reserved.